Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant's Acculink Is Exclusive CREST Stent; Trial Begins in Six Months

This article was originally published in The Gray Sheet

Executive Summary

Guidant has the option of evaluating an emboli protection device along with its Acculink self-expanding carotid stent in the 2,500-patient Carotid Revascularization Endarterectomy Stenting Trial (CREST), according to study investigators.

You may also be interested in...

J&J Polishes SAPPHIRE Carotid Trial For HCFA Conditional Coverage Appraisal

Johnson & Johnson Cordis plans to submit an investigational device exemption application to FDA in March or April for the SAPPHIRE carotid stent trial, as discussions continue with the Health Care Financing Administration to secure reimbursement coverage.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts